Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Clinical Lymphoma
|
April 10, 2004
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
Michael Keating, Stephen Coutré, Kanti Rai, et al.
International Journal of Cancer
|
June 12, 2008
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H Daneshmanesh, Eva Mikaelsson, Mahmood Jeddi-Tehrani, et al.
Blood
|
April 20, 2004
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Geoff Hale, Peppy Rebello, Lee R Brettman, et al.
Blood
|
February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Youn H Kim, Madeleine Duvic, Erik Obitz, et al.
Blood Advances
|
February 21, 2025
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: Focus on the very early period and Omicron era
Pontus Hedberg, Lisa Blixt, Sandra Eketorp Sylvan, et al.
Cancer Research
|
September 7, 2012
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model
Pedram Kharaziha, Hendrik De Raeve, Charlotte Fristedt, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
July 12, 2002
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
Heinz Ludwig, Kanti Rai, Joan Blade, et al.
Journal of Hematology
|
September 11, 2023
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Maria Andersson, Jinghua Wu, David Wullimann, et al.
British Journal of Haematology
|
June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones, Anthony Mato, Steven Coutre, et al.
The Lancet. Oncology
|
September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Clinical Lymphoma
|
April 10, 2004
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia
Michael Keating, Stephen Coutré, Kanti Rai, et al.
International Journal of Cancer
|
June 12, 2008
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H Daneshmanesh, Eva Mikaelsson, Mahmood Jeddi-Tehrani, et al.
Blood
|
April 20, 2004
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Geoff Hale, Peppy Rebello, Lee R Brettman, et al.
Blood
|
February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Youn H Kim, Madeleine Duvic, Erik Obitz, et al.
Blood Advances
|
February 21, 2025
Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: Focus on the very early period and Omicron era
Pontus Hedberg, Lisa Blixt, Sandra Eketorp Sylvan, et al.
Cancer Research
|
September 7, 2012
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model
Pedram Kharaziha, Hendrik De Raeve, Charlotte Fristedt, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
July 12, 2002
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
Heinz Ludwig, Kanti Rai, Joan Blade, et al.
Journal of Hematology
|
September 11, 2023
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Maria Andersson, Jinghua Wu, David Wullimann, et al.
British Journal of Haematology
|
June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Jeffrey Jones, Anthony Mato, Steven Coutre, et al.
The Lancet. Oncology
|
September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
Page
of 8